

Special Issue

The Role of the Bone Marrow Microenvironment in Normal Hematopoiesis and Leukemia Development

Message from the Guest Editors

The bone marrow microenvironment (BMM) is considered the main sanctuary of hematopoietic stem and progenitor cells (HSPCs). The BMM is composed of many different cell types, including stromal cells, endothelial cells, and neuronal cells, and regulates the generation of blood through direct contact or the secretion of different signaling molecules. Any alterations in the BMM due to aging, infection, or malignant transformation alter HSPC potential and consequently hematopoiesis. Due to their uncanny resemblance to HSPCs, leukemia cells reside in the same microenvironment. Not only do some physiological conditions, such as the aging of the BMM, favor leukemia development, but the leukemic cells in turn modulate the BMM in a way that supports their progression. Understanding the interplay between normal and malignant cells in the bone marrow microenvironment can hopefully provide insight into new therapeutic targets in different malignancies of the blood. This Special Issue aims to shed light on the role of this complex environment and how it works under normal and malignant conditions.

Guest Editors

Dr. Mohammad Houshmand

Department of Regenerative Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Dr. Jelena Milosevic

Department of Regenerative Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Deadline for manuscript submissions

closed (31 July 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/137656

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).